Drug General Information
Drug ID	D0V7PL
Former ID	DIB007767
Drug Name	Lefradafiban
Synonyms	BIBU-104; BIBU-104XX; BIBV-104
Drug Type	Small molecular drug
Indication	Angina pectoris [ICD9: 413; ICD10:I20]		Phase 1	[524952]
Company	Boehringer Ingelheim Corp
Structure		Download 2D MOL 3D MOL
Formula	C23H25N3O6
Canonical SMILES	N(C(=N)c1ccc(c2ccc(OC[C@H]3NC(=O)[C@H](CC(=O)OC)C3)cc2)<br />cc1)C(=O)OC
CAS Number	CAS 149503-79-7
PubChem Compound ID	9576916
Target and Pathway
Target(s)	Glycoprotein IIb/IIIa receptor	Target Info	Modulator	[526006]
Reactome	Platelet degranulation
	Elastic fibre formation
	PECAM1 interactions
	Molecules associated with elastic fibres
	Integrin cell surface interactions
	Syndecan interactions
	ECM proteoglycans
	Integrin alphaIIb beta3 signaling
	GRB2:SOS provides linkage to MAPK signaling for Integrins
	p130Cas linkage to MAPK signaling for integrins
	VEGFA-VEGFR2 Pathway
	MAP2K and MAPK activation
WikiPathways	Focal Adhesion
	Hematopoietic Stem Cell Differentiation
	Human Complement System
	Extracellular matrix organization
	Arrhythmogenic Right Ventricular Cardiomyopathy
	Integrin-mediated Cell Adhesion
	L1CAM interactions
	Integrin cell surface interactions
	Integrin alphaIIb beta3 signaling
References
Ref 524952	ClinicalTrials.gov (NCT02264106) Influence of Pantoprazole on the Pharmacokinetics of Fradafiban After Multiple Oral Doses of Lefradafiban Over 5 Days in Healthy Subjects. U.S. National Institutes ofHealth.
Ref 526006	Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty. Heart. 2001 Apr;85(4):444-50.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.